MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/bju.70276

Медицинская библиотека · BJU international · 2026

Outcomes and progression predictors in a New Zealand active surveillance programme for prostate cancer.

Xu Kain, Shah Nikhar, Han Dug Yeo, Koya Madhu, Beaven Tony

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

To describe outcomes and identify predictors of histological progression in men on active surveillance (AS) for International Society of Urological Pathology Grade Group (ISUP GG) 1 prostate cancer in New Zealand (NZ), as AS is the standard management for favourable-risk prostate cancer, yet NZ-specific outcome data remain limited.

PATIENTS AND

METHODS

A retrospective study of the North Shore Hospital AS programme (2014-2020) was conducted. Records were reviewed in 2024. In total, 296 men with ISUP GG 1 disease on AS were included. Primary endpoints were histological progression to ISUP GG ≥2, treatment conversion, and disease-related mortality.

RESULTS

Over a mean 7.4-year follow-up, 36.5% progressed, 33.4% required treatment, 12.1% recurred after treatment, and one patient died from metastatic disease. Within the cohort, a low-risk subgroup of 93 patients with ISUP GG 1 prostate cancer had low prostate-specific antigen (PSA) density and no suspicious magnetic resonance imaging (MRI) lesions. Of these patients, 16 (17.2%) progressed. On multivariate analysis, independent predictors of progression were PSA density ≥0.15 ng/mL/mL (odds ratio [OR] 3.45) and Prostate Imaging-Reporting and Data System 3-5 lesions (OR 3.52).

CONCLUSION

Active surveillance is a safe option for low-risk prostate cancer, our data are consistent with outcomes consistent with the Prostate Cancer Outcomes Registry and international data. PSA density and multiparametric MRI were the strongest predictors of progression; tumour volume by percentage of positive cores was not independently predictive. New draft Prostate Cancer Foundation of Australia guidelines recommend against biopsy in men with PSA density <0.15 ng/mL/cc and no PIRADS 3-5 lesion on MRI[7], in our cohort this included many men with ISUP 1 cancer. They had a 17.2% progression rate to ISUP ≥2, and their clinically significant disease might have been missed without close surveillance.

Для цитирования: Xu Kain, Shah Nikhar, Han Dug Yeo, Koya Madhu, Beaven Tony. Outcomes and progression predictors in a New Zealand active surveillance programme for prostate cancer.. BJU international. 2026. DOI: 10.1111/bju.70276.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.